← Back to patent-cliff list
CDR-132L
Tier C — Watch / tradeCDR-132L
Cardior Pharmaceuticals Gmbh
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：MIR132
Indications (approved)：Heart failure, Myocardial infarction, Diastolic heart failure
Regional status
US
Phase II
2025-06-27
EU
Phase II
2022-07-11
China
Phase I
2026-09-16
Japan
Phase II
2025-06-27
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CDR-132L?
Approved indications include: Heart failure, Myocardial infarction, Diastolic heart failure.
When does the CDR-132L patent expire?
No public expiry year is available for CDR-132L yet; this page updates once verified.
How do I get a quote for CDR-132L intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05